Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Discloses GenturaDx Loss of $19.8M in 2011, $18.5M in H1 2012

NEW YORK (GenomeWeb News) – Luminex today disclosed the finances of GenturaDx, a molecular diagnostic test firm that it acquired for $50 million during the summer.

In a document filed with the US Securities and Exchange Commission, Luminex said that for full-year 2011, GenturaDx recorded no revenues and a net loss of $19.8 million. The company spent $10.1 million on R&D and $3.5 million on SG&A.

For the first six months of 2012, GenturaDx also saw no revenues and a net loss of $18.5 million. R&D costs totaled $6.2 million, while SG&A costs were $5.0 million.

On a pro forma basis, treating GenturaDx as if it were part of Luminex during full-year 2011, the combined company posted $184.3 million in revenues and a profit of $5.2 million, or $.12 per share, Luminex said. R&D spending was $43.5 million, and SG&A totaled $68.4 million.

Luminex earlier this year reported full-year 2011 revenues of $184.3 million and a profit of $14.5 million, or $.34 per share, on a GAAP basis, not including GenturaDx. R&D costs totaled $33.4 million, and SG&A spending totaled $64.9 million.

For the six months ended June 30, 2012 the combined companies had revenues of $97.0 million on a pro forma basis, and a profit of $2.4 million, or $.06 per share. The combined companies spent $25.2 million on R&D and $36.2 million on SG&A.

On a GAAP basis, Luminex recorded $97.0 million in revenues during the first half of 2012 resulting in a profit of $6.5 million, or $.15 per share. R&D costs came in at $19.1 million, while SG&A costs were $34.8 million.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.